ClinicalTrials.gg
Active, not recruitingNCT05384756Updated Jul 30, 2026

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

A Phase 1 interventional study of Alemtuzumab and Hematopoietic Cell Transplantation in Sickle Cell Disease, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing alemtuzumab in Anemia, Sickle Cell — 6 open to participants now, 14 under way, none of them phase 3. Alemtuzumab · Anemia, Sickle Cell.

Planned enrollment
15th of 22
20 · median 44
Started
2022
the only one that year
Phase 1
3 of 22
none open now
Primary completion
2026-12
later than 7 of 13 live
Registered
20th of 22
by date
Lead sponsor
1 of 22
City of Hope Medical Center

Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, this one is the 15th largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 1, reaches primary completion later than 7 of the 13 other live ones, and was the 20th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

6 of the 22 studies testing alemtuzumab in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About alemtuzumab

Alemtuzumab: first FDA approval 2001 (LEMTRADA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing alemtuzumab in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

This phase I trial tests the safety and effectiveness of total marrow and lymphoid irradiation (TMLI) and alemtuzumab as a conditioning regimen in patients with sickle cell disease. Conditioning regimens are treatments used to prepare a patient for stem cell transplantation. A stem cell transplant is a procedure in which a person receives blood stem cells, which make any type of blood cell. A conditioning regimen may include chemotherapy, monoclonal antibody therapy, and radiation to the entire body. It helps make room in the patient's bone marrow for new blood stem cells to grow, and helps prevent the patient's body from rejecting the transplanted cells. Alemtuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Graft-versus-host disease (GVHD) is a complication that may occur after hematopoietic cell transplantation (HCT) in which donated cells view the recipient's cells as foreign and attack them. Giving TMLI and alemtuzumab may help reduce organ damage that can be caused by radiation and decrease the risk of GVHD.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the safety and feasibility of a fixed TMLI dose of 600 cGy with alemtuzumab as non-myeloablative conditioning (NMC) regimen in patients with sickle cell disease to achieve stable engraftment by Day +100 post HCT.

SECONDARY OBJECTIVES:

I. Assess the hematopoietic recovery by determining donor neutrophil engraftment, platelet engraftment.

II. Assess irradiation doses to non-target organs (lungs, heart, liver, spleen, kidneys, and gonads).

III. Assess the incidence of acute GvHD (grade II - IV) during the first 100 days after transplantation and chronic GvHD at 1 year post-HCT.

IV. Assess overall, event-free, and disease free survival at 1 year post-HCT. V. Assess donor chimerism at day +100 and 1 and 2 years after HCT.

EXPLORATORY OBJECTIVES:

I. Assess immune reconstitution post HCT on baseline, then on days +15, +30, +60, and +180, and 1-year post-HCT. II. Assessment of quality of life at baseline, Day+100, Day +180 and at 1-year post-HCT.

III. Define the impact of sickle cell disease (SCD) including inflammation on the bone marrow microenvironment and hematopoietic cells function at baseline.

IV. Monitor treatment response noninvasively on the recovery of bone marrow microenvironment (hematopoietic and vascular).

V. Monitor treatment response noninvasively on cerebral blood flow (CBF).

OUTLINE:

Patients receive alemtuzumab intravenously (IV) over 4 hours once daily (QD) on days -7 to -3. Patients undergo TMLI twice daily (BID) on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.

After study treatment, patients are followed up on day 30, and for up to 2 years.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Registered into Risk Evaluation and Mitigation Strategies (REMS) program
  • Age: 12-40 years
  • (ECOG) performance status =\< 2
  • Have a diagnosis of sickle cell disease, be at a high risk for disease related morbidity or mortality, which must be defined by one of the following disease status criteria:

    • Significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; or increased transcranial Doppler velocity (> 200 m/s).
    • History of one or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea).
    • History of one or more severe vaso-occlusive pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea).
    • Recurrent priapism requiring medical therapy.
    • Osteonecrosis of two or more joints despite the institution of supportive care measures.
    • Prior treatment with regular red blood cell (RBC) transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
    • Echocardiograph finding of tricuspid valve regurgitation jet (TRJ) velocity >= 2.5 m/sec.
  • Have a related donor who is matched on at least 8/10 human leukocyte antigen (HLA)-A, B, C, and DRB1 Loci
  • Total =\< 2.5 x upper limit normal (( (unless has Gilbert's disease) (performed within 30 days prior to day 1 of protocol)
  • (AST) =\< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)
  • Alanine aminotransferase (ALT) =\< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)
  • (CrCl) of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 30 days prior to day 1 of protocol)
  • If not receiving anticoagulants: (INR) OR Prothrombin (PT) =\< 1.5 x ULN (performed within 30 days prior to day 1 of protocol)

    • If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
  • If not receiving anticoagulants: Activated Partial Thromboplastin Time (aPTT) =\<1.5 x ULN (performed within 30 days prior to day 1 of protocol)

    • If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
  • (LVEF) >= 50% (performed within 30 days prior to day 1 of protocol)

    • Note: To be performed within 28 days prior to Day 1 of protocol therapy.
  • If able to perform pulmonary function tests: (FEV1), force vital capacity (FVC), and diffused lung capacity of carbon monoxide (DLCO) (diffusion capacity) >= 50% of predicted (corrected for )

    • If unable to perform pulmonary function tests: Oxygen (O 2) saturation > 92% on room air
    • Note: To be performed within 28 days prior to Day 1 of protocol therapy.
  • Seronegative for (HIV) antigen (Ag)/antibody (Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative), and syphilis (rapid plasma regain [RPR])

    • If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
  • Meets other institutional and federal requirements for infectious disease titer requirements

    • Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
  • Women of (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be require.
  • Agreement by females and males of childbearing potential to use an effective method of or abstain from heterosexual activity for the course of the study through at least Six months after the last dose of protocol therapy.

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • DONOR: Age =\< 60 years
  • DONOR: Medical history and physical examination confirm good health status as defined by institutional standards
  • DONOR: Serologies for: Hepatitis B (HBV) Core Antibody, HIV I/II Antibody, human T-lymphotropic virus (HTLV) - I/II antibody, HCV antibody, Hepatitis B surface antigen, Serologic Test for Syphilis, HIV-1/HCV/HBV nucleic acid, West Nile virus nucleic acid, Trypanosoma cruzi antibody, Cytomegalovirus (CMV) antibody, (AKA: Donor Room Serologies)
  • DONOR: Female donors of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (b-HCG) test within 30 days of initiation of conditioning, 30 days of patients admission for conditioning and 7 days of mobilization or bone marrow harvest.
  • DONOR: The donor must be informed of the nature of this study and have signed a consent form in accordance with Federal Guidelines and the guidelines of the participating institution

Exclusion criteria

Exclusion Criteria:

  • Prior or autologous stem cell transplant
  • Patients who are receiving any other agents, or concurrent biological, chemotherapy, or radiation therapy.
  • History of allergic reactions attributable to compounds of similar chemical or biologic composition to study agent
  • Patients with any active are ineligible for this study, other than non-melanoma skin cancers
  • Medical problem or neurologic/psychiatric dysfunction which would impair patient ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery which in the opinion of the principal investigator would place the recipient at unacceptable risk.
  • Active infection requiring antibiotics
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
  • DONOR: Evidence of active infection
  • DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis if donating peripheral stem cells or unlikely to tolerate general anesthesia and bone marrow collection if donating a bone marrow
  • DONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte colony-stimulating Factor (G-CSF) therapy if donating peripheral stem cells or general anesthesia and bone marrow collection if donating a bone marrow
  • DONOR: Lactating female or, if of , is unwilling to implement adequate
  • DONOR: positive
  • DONOR: Prior radiation therapy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment (TMLI, alemtuzumab)

    Patients receive alemtuzumab IV over 4 hours QD on days -7 to -3. Patients undergo TMLI BID on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.

    Drug: Alemtuzumab · Procedure: Hematopoietic Cell Transplantation · Radiation: Intensity-Modulated Radiation Therapy · Drug: Sirolimus

Interventions

  • Given IV

    Also known as: Anti-CD52 Monoclonal Antibody, Campath, Campath-1H, LDP-03, Lemtrada, MabCampath, Monoclonal Antibody Campath-1H

  • ProcedureHematopoietic Cell Transplantation

    Undergo HCT

    Also known as: HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo TMLI

    Also known as: IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • Medication to prevent the development of graft-versus-host disease (GVHD)

    Also known as: AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Will be scored on the Bearman Scale National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. The proportion of patients with the unacceptable adverse events will be calculated along with the appropriate Clopper-Pearson 90% confidence intervals.

    Time frame: Up to day 100 post-transplant

  2. Feasibility

    Feasibility will be defined as engraftment that would be sufficient to reduce sickle cell disease (SCD) burden (Any donor chimerism with Hgb S =\< 30%).

    Time frame: Up to 2 years

Secondary outcomes

  1. Platelet engraftment

    Platelet engraftment will be defined as independence from platelet transfusion for at least 7 days with a platelet count of more than \>20 × 10\^9/L

    Time frame: Up to 2 years

  2. Time to acute graft-versus-host disease (grades 2-4 and 3-4) until day +100 after transplant

    Acute Graft versus Host Disease (aGVHD) of grades 2-4 and 3-4: Documented/biopsy proven acute graft versus host disease is graded according to the Consensus Grading. Time to event is measured from date of stem cell infusion to document/biopsy proven acute GVHD onset date (within the first 100 days post-transplant) and will be used to estimate the cumulative incidence.

    Time frame: Up to 2 years

  3. Time to chronic graft-versus-host disease for up to one year after transplant

    Chronic Graft versus Host Disease (cGVHD): chronic Graft versus Host Disease (aGVHD) of grades 2-4 and 3-4: Documented/biopsy proven chronic graft versus host disease is scored according to NIH Consensus Staging. Time to event is measured from date of stem cell infusion to the documented/biopsy proven chronic GVHD onset date and will be used to estimate the cumulative incidence.

    Time frame: Up to 2 years

  4. Overall survival (OS)

    Patients are considered a failure for this endpoint if they die, regardless of cause.

    Time frame: From start of protocol therapy to death, or last follow-up, whichever comes first, assessed up to 2 years

  5. Event-free survival (EFS)

    Patients are considered a failure for this endpoint if they graft failure, or die, regardless of cause. Time to this event is the time from start of protocol therapy to death, graft failure, or last follow-up, whichever comes first.

    Time frame: From start of protocol therapy to death, graft failure, or last follow-up, whichever comes first, assessed up to 2 years

  6. Disease-free Survival (DFS)

    Patients are considered a failure for this endpoint if they die (regardless of cause) or experience disease progression or relapse.

    Time frame: From date of stem cell infusion to death, disease relapse/progression, or last follow-up, whichever comes first, assessed up to 2 years

Other outcomes

  1. Immune cell reconstitution

    Immune cell reconstitution will be assessed by flow cytometry analysis

    Time frame: Up to 2 years

  2. Quality of life - PedsQL

    Items on the PedsQL Generic Core Scales are reverse scored and transformed to a 0-100 scale. Higher scores indicate better health related quality of life: 0 ("Never") = 100 1. ("Almost Never") = 75 2. ("Sometimes") = 50 3. ("Often") = 25 4. ("Almost Always") = 0 For adults 16-item QOLS patients will be given a copy of the 7-point response scale \["delighted" (7), "pleased" (6), "mostly satisfied" (5), "mixed" (4), "mostly dissatisfied" (3), "unhappy" (2), "terrible" (1).\] The QOLS scores will be summed so that a higher score indicates higher quality of life. Average total score for healthy populations is about 90. However, like many QOL instruments, the means tend to be quite negatively skewed with most patients reporting some degree of satisfaction with most domains of their lives.

    Time frame: Up to 2 years

  3. Bone marrow environment inflation - levels of inflammatory cytokines

    The long-term impact of Sickle Cell Disease on patients bone marrow will be measured by evaluation of the levels of inflammatory cytokines in the bone marrow before treatment with TMLI and alemtuzumab.

    Time frame: Baseline only (pre-conditioning)

  4. Bone marrow environment inflation - stem cell function

    The long-term impact of Sickle Cell Disease on patients bone marrow will be measured by evaluation of the stem cell function in the bone marrow before treatment with TMLI and alemtuzumab.

    Time frame: Baseline only (pre-conditioning)

  5. Treatment response on bone marrow environment and CBF

    Treatment response on bone marrow environment and CBF will be assessed by Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). All imaging will be performed before the start of the treatment and post-transplant at days 30, 100, 180, and at one year, coinciding with time points when clinical standard biopsy samples are obtained.

    Time frame: Up to 1 year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 58 phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2022
First posted
May 20, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05384756
Responsible party
Sponsor
First posted
May 20, 2022
Start date
Jul 13, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Anna Pawlowska
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alemtuzumab

Start the discussion